Literature DB >> 27098446

Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study.

LieSbeth H Schrijvers1, Marlene Beijlevelt-van der Zande2, Marjolein Peters2, Janske Lock3, Marjon H Cnossen3, Marieke J Schuurmans4,5, Kathelijn Fischer1,6.   

Abstract

Prevention of bleeding and joint damage in severe haemophilia is dependent on adherence to prophylactic replacement therapy. The aim of this study was to assess adherence to prophylaxis, including associations with age, bleeding and clotting factor consumption (CFC). In three Dutch haemophilia centres, semi-structured interviews about adherence to prophylaxis in the previous 2 weeks were conducted with patients or parents of a child with haemophilia. Patients were classified, according to pre-specified definitions, as adherent, sub-optimally adherent or non-adherent based on missing, timing, and dose of infusions. Association of annual bleeding rates, mean CFC, person performing the infusion (parents verus patients) with adherence categories were analysed. Overall, 241 patients with haemophilia using prophylaxis were studied. Parents were more adherent (66%; n = 48/73) than patients (43%; n = 72/168). Sub-optimal adherence occurred in 29% of parents and 37% of patients and was characterized by changes in timing of infusion (mostly from morning to evening), while missing <6% of infusions. Non-adherence occurred less often: in 5% of parents and 20% of patients. Reduced adherence was associated with lower CFC, but not with joint bleeding. In conclusion, non-adherence in haemophilia was relatively rare, yet 1/3 of patients struggled to administer prophylaxis at the appropriate time of day.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  adherence; chronic; hemophilia; prophylaxis; von Willebrand

Mesh:

Substances:

Year:  2016        PMID: 27098446     DOI: 10.1111/bjh.14072

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

Review 2.  Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Authors:  Massimo Morfini; Stefano Gherardini
Journal:  Ther Adv Hematol       Date:  2018-06-05

3.  Changing care pathways and between-center practice variations in intensive care for traumatic brain injury across Europe: a CENTER-TBI analysis.

Authors:  Jilske A Huijben; Eveline J A Wiegers; Hester F Lingsma; Giuseppe Citerio; Andrew I R Maas; David K Menon; Ari Ercole; David Nelson; Mathieu van der Jagt; Ewout W Steyerberg; Raimund Helbok; Fiona Lecky; Wilco Peul; Tatiana Birg; Tommaso Zoerle; Marco Carbonara; Nino Stocchetti
Journal:  Intensive Care Med       Date:  2020-02-25       Impact factor: 17.440

4.  Manual and educational therapy in the treatment of hemophilic arthropathy of the elbow: a randomized pilot study.

Authors:  Rubén Cuesta-Barriuso; Antonia Gómez-Conesa; José-Antonio López-Pina
Journal:  Orphanet J Rare Dis       Date:  2018-09-03       Impact factor: 4.123

5.  Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.

Authors:  Giovanni Di Minno; Elena Santagostino; Massimo Morfini; Cosimo Ettorre; Dorina Cultrera; Erminia Baldacci; Eleonora Russo; Cristiano Gallucci
Journal:  Patient Prefer Adherence       Date:  2019-01-31       Impact factor: 2.711

6.  Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII).

Authors:  Jane R Wells; Adam Gater; Chris Marshall; Theo Tritton; Parth Vashi; Sophia Kessabi
Journal:  Patient       Date:  2019-12       Impact factor: 3.883

Review 7.  Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes.

Authors:  Maria Sol Cruz; Josefina Santillan; Julieta Lesser; Juan Pablo Ortiz; Laura Forzani
Journal:  Clin Pract       Date:  2021-05-08

Review 8.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123

9.  Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment.

Authors:  Michelle Witkop; George Morgan; Jamie O'Hara; Michael Recht; Tyler W Buckner; Diane Nugent; Randall Curtis; Brian O'Mahony; Mark W Skinner; Brendan Mulhern; Matthew Cawson; Talaha M Ali; Eileen K Sawyer; Nanxin Li
Journal:  Haemophilia       Date:  2021-07-26       Impact factor: 4.263

Review 10.  Categorizing factors of adherence to parenteral treatment in growth hormone deficiencies and hemophilia: What should be the targets for future research?

Authors:  Serge Sultan; Mira El-Hourani; Émélie Rondeau; Nicolas Garnier
Journal:  Patient Prefer Adherence       Date:  2018-10-08       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.